DIY mRNA Production
A technical overview of what mRNA synthesis looks like in a research-lab or well-resourced DIY setting. What the workflow requires, what can go wrong, and why this is not a casual undertaking.
How It Works
In Vitro Transcription — uses T7 RNA polymerase + NTPs + a DNA template. Commercial kits (e.g., NEB HiScribe) produce mg quantities of mRNA in a tube reaction over hours.
mRNA stability requires a 5' cap. Done via cap analog (ARCA) during IVT, or by post-transcriptional capping with vaccinia capping enzyme. Cap-0 vs Cap-1 matters for immunogenicity.
Remove unincorporated NTPs, template DNA, and contaminating dsRNA. Standard: LiCl precipitation, then silica column, then sometimes HPLC. dsRNA is a major immunogenicity driver — hard to fully remove.
mRNA alone degrades in blood. Lipid nanoparticles (LNP) protect and deliver. Requires microfluidic mixing, specific ionizable lipids (SM-102, ALC-0315), PEG-lipid, cholesterol, and DSPC. Formulation is where most DIY attempts fail.
What the Data Shows
Key Takeaways
- IVT synthesis with commercial kits is the most tractable step
- Capping, purification, and LNP formulation are where quality breaks down
- Modified nucleotides (pseudouridine) reduce immunogenicity
- dsRNA contamination is the #1 driver of inflammation on injection
- LNP formulation is capital-intensive and hard to DIY correctly
- Small-scale mRNA production has no clinical quality assurance
- LNP quality varies by orders of magnitude across setups — affects biodistribution
- Producing mRNA for human injection is illegal in most jurisdictions
- BSL-1+ conditions are minimum — contamination compromises everything
- Open-source literature is educational; real application requires regulated infrastructure
Frequently Asked Questions
Is this legal?
Producing mRNA as a research compound in the US is legal in a research-lab context. Injecting DIY-produced mRNA into humans is not legal — it falls under FDA drug regulation. DIYbio communities have explored this academically.
What's the hardest step?
LNP formulation. IVT synthesis is kit-based and reproducible; capping is solved by modern protocols; purification is work but feasible. LNPs require microfluidic mixing, specific lipid chemistry, and quality control that's hard to replicate in small-lab settings.
Can I do this at home?
Practically — no, not in a way that produces safe injectable product. The capital, expertise, and QC required are substantial. The workflow exists in research labs and specialized contract manufacturers for a reason.
Why does HighPeptides cover this?
mRNA and peptide therapeutics are related technologies — both are biologic modalities with overlapping production principles. Understanding mRNA production helps contextualize how peptide therapeutics are made and why vendor quality varies.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
This page is educational. It describes the technical workflow of mRNA production as covered in open literature. It is not a how-to for producing therapeutics for human use.
Producing injectable biologics outside of regulated infrastructure is illegal in most jurisdictions and carries real health risks. Not medical or technical advice.